See more : Fortinet, Inc. (FTNT) Income Statement Analysis – Financial Results
Complete financial analysis of Schrödinger, Inc. (SDGR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Schrödinger, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
- Solomon Systech (International) Limited (2878.HK) Income Statement Analysis – Financial Results
- Vardhman Special Steels Limited (VSSL.BO) Income Statement Analysis – Financial Results
- Occidental Petroleum Corporation (OPC.DE) Income Statement Analysis – Financial Results
- ONTSU Co.,Ltd. (7647.T) Income Statement Analysis – Financial Results
- Allied Properties Real Estate Investment Trust (AP-UN.TO) Income Statement Analysis – Financial Results
Schrödinger, Inc. (SDGR)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.schrodinger.com
About Schrödinger, Inc.
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 216.67M | 180.96M | 137.93M | 108.10M | 85.54M | 66.64M | 55.69M |
| Cost of Revenue | 75.97M | 79.93M | 72.31M | 44.62M | 36.45M | 23.70M | 15.89M |
| Gross Profit | 140.69M | 101.02M | 65.62M | 63.47M | 49.09M | 42.94M | 39.80M |
| Gross Profit Ratio | 64.93% | 55.83% | 47.57% | 58.72% | 57.39% | 64.43% | 71.46% |
| Research & Development | 181.77M | 126.37M | 90.90M | 64.70M | 39.40M | 34.52M | 27.67M |
| General & Administrative | 99.15M | 90.83M | 64.01M | 41.90M | 27.04M | 18.55M | 14.44M |
| Selling & Marketing | 37.23M | 30.64M | 22.15M | 17.80M | 21.36M | 17.83M | 16.72M |
| SG&A | 136.37M | 121.47M | 86.16M | 59.69M | 48.40M | 36.38M | 31.15M |
| Other Expenses | 0.00 | 3.95M | 1.06M | 2.25M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 318.14M | 247.84M | 177.06M | 124.39M | 87.81M | 70.91M | 58.82M |
| Cost & Expenses | 394.11M | 327.77M | 249.37M | 169.01M | 124.26M | 94.61M | 74.71M |
| Interest Income | 0.00 | 3.95M | 1.06M | 2.25M | 1.88M | 433.00K | 359.00K |
| Interest Expense | 0.00 | 3.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.55M | 4.34M | 2.85M | 3.66M | 3.64M | 2.89M | 1.69M |
| EBITDA | -171.90M | -142.47M | -108.60M | -57.26M | -35.08M | -25.08M | -17.34M |
| EBITDA Ratio | -79.34% | -80.01% | -86.97% | -79.12% | -52.60% | -36.41% | -28.18% |
| Operating Income | -177.45M | -149.12M | -111.44M | -60.92M | -38.72M | -27.97M | -19.02M |
| Operating Income Ratio | -81.90% | -82.41% | -80.80% | -56.35% | -45.26% | -41.97% | -34.15% |
| Total Other Income/Expenses | 220.37M | -2.31M | 10.64M | 34.62M | 12.74M | -379.00K | 1.96M |
| Income Before Tax | 42.92M | -149.13M | -100.81M | -26.29M | -25.97M | -28.35M | -17.06M |
| Income Before Tax Ratio | 19.81% | -82.41% | -73.09% | -24.32% | -30.36% | -42.54% | -30.63% |
| Income Tax Expense | 2.20M | 63.00K | 411.00K | 345.00K | -291.00K | 77.00K | 332.00K |
| Net Income | 40.72M | -149.19M | -101.22M | -26.64M | -25.68M | -28.43M | -17.39M |
| Net Income Ratio | 18.79% | -82.45% | -73.38% | -24.64% | -30.02% | -42.66% | -31.23% |
| EPS | 0.57 | -2.10 | -1.43 | -0.44 | -0.41 | -0.59 | -0.43 |
| EPS Diluted | 0.54 | -2.10 | -1.43 | -0.44 | -0.41 | -0.59 | -0.43 |
| Weighted Avg Shares Out | 71.78M | 71.17M | 70.59M | 60.02M | 63.27M | 48.47M | 40.38M |
| Weighted Avg Shares Out (Dil) | 74.99M | 71.17M | 70.59M | 60.02M | 63.27M | 48.47M | 40.38M |
Better AI Biotech Stock: Schrödinger vs. Recursion Pharmaceuticals
This Artificial Intelligence Biotech Stock Is Crushing the Market, but Is It a Buy?
Why These 3 Stocks Are the Best Ways to Play AI Right Now
DPST And BTO: Schrodinger's Regional Banks
7 Stocks in Hot Water: Dump This Dead Weight as Costs Skyrocket
Why Shares of Schrödinger Rose This Week
3 Revolutionary Companies With Trillion-Dollar Potential
Schrodinger, Inc. (SDGR) Surges 6.6%: Is This an Indication of Further Gains?
3 Pharma Stocks That Will Boom Thanks to AI
Schrodinger: Reiterate Buy Rating On Strong Software Revenue Growth Ahead
Source: https://incomestatements.info
Category: Stock Reports